I/We Claim:
1. A self-assembled peptide nano-architecture comprising:
a) an assembly of peptide-encapsulated drug; and
b) an assembly of peptide-cisplatin conjugate,
wherein the peptide is having an amino acid sequence as set forth in SEQ ID NO: 1, and the nano-architecture is in form of a vesicle.
2. The self-assembled peptide nano-architecture as claimed in claim 1, wherein the nano-architecture has a size higher than 100 nm.
3. The self-assembled peptide nano-architecture as claimed in claim 1, wherein the assembly of peptide-encapsulated drug comprises peptide-encapsulated drug having a concentration in a range of 0.01-0.05 mg/ml with respect to the self-assembled peptide nano-architecture.
4. The self-assembled peptide nano-architecture as claimed in claim 1, wherein the assembly of peptide-cisplatin conjugate comprises peptide-cisplatin conjugate having a concentration in a range of 0.01-0.05 mg/ml with respect to the self-assembled peptide nano-architecture.
5. The self-assembled peptide nano-architecture as claimed in claim 1, wherein the drug is at least one selected from doxorubicin, camptothecin, or irinotecan.
6. The self-assembled peptide nano-architecture as claimed in claim 5, wherein the drug is doxorubicin.
7. The self-assembled peptide nano-architecture as claimed in claim 1, wherein in the peptide-cisplatin conjugate, the peptide and cisplatin are covalently linked.
8. A method for preparing the self-assembled peptide nano-architecture as claimed in claim 1, said method comprising:

a) obtaining the drug and the peptide;
b) encapsulating the drug with the peptide, to obtain an assembly of peptide-encapsulated drug;
c) obtaining cisplatin and the peptide;

d) conjugating cisplatin with the peptide, to obtain peptide-cisplatin conjugate;
e) contacting the peptide-cisplatin conjugate with vesicles of the peptide of step (c), to obtain an assembly of peptide-cisplatin conjugate; and
f) mixing the assembly of peptide-encapsulated drug and the assembly of peptide-cisplatin conjugate, to obtain the self-assembled peptide nano-architecture.

9. A composition comprising: (a) a peptide; (b) a drug; and (c) a peptide-cisplatin conjugate to form a drug encapsulating self-assembled peptide nano-architecture in form of a vesicle, wherein the peptide is having an amino acid sequence as set forth in SEQ ID NO: 1.
10. The self-assembled peptide nano-architecture as claimed in claim 1, wherein the nano-architecture is used for treating cancer.
11. A method for delivering a drug in a subject, said method comprising:

a) obtaining the self-assembled peptide nano-architecture as claimed in claim 1; and
b) administering the nano-architecture to the subject for delivering the drug in the subject.
12. A method for delivering cisplatin in a subject, said method comprising:
a) obtaining the self-assembled peptide nano-architecture as claimed in claim 1; and
b) administering the nano-architecture to the subject for delivering cisplatin in the subject.
13. A method for treating cancer in a subject, said method comprises:
a) obtaining the self-assembled peptide nano-architecture as claimed in claim 1; and
b) administering the nano-architecture to the subject for treating cancer in the subject.

14. Use of the self-assembled peptide nano-architecture as claimed in claim 1 for delivering a drug into a subject.
15. Use of the self-assembled peptide nano-architecture as claimed in claim 1 for delivering cisplatin into a subject.